09-12-2011 Press Release
|
For Immediate Release:
Diffinity Genomics Awarded >$200K in NIH Grants
Abstract: Diffinity Genomics™, Inc. announced this week that the National Institutes of Health’s National Human Genome Research Institute has awarded the company $205,843 in two separate Phase I grants to continue the development of rapid nucleic acid purification methods. Rochester, NY -- September 12, 2011 Diffinity Genomics™, Inc. announced this week that the National Institutes of Health’s National Human Genome Research Institute has awarded the company $205,843 in two separate Phase I grants to continue the development of rapid nucleic acid purification methods. One grant, totaling $104,241, is allocated to the development of purification methods following enzyme-catalyzed nucleic acid synthesis, while the other grant of $101,602 is designated for projects investigating rapid DNA purification from gel matrices. Future Diffinity products developed from these activities will further increase the efficiency of DNA purification for analysis in high throughput systems such as DNA microarrays and Next Generation Sequencing. In 2010, the company was awarded over $700,000 from the NIH to assist in the commercialization of Diffinity Genomics’ first product, the RapidTip. The Diffinity RapidTip™ for PCR Purification quickly and efficiently purifies amplified DNA from PCR product in a one-step, one-minute process that requires only a single functional pipette tip and a standard pipettor. The product has been enthusiastically accepted by customers in the PCR purification market. Diffinity Genomics has collaborated with researchers at the University of Rochester, Rochester, NY, on the development and subsequent licensing of the technology for these projects. Dr. Lewis J. Rothberg, the principal investigator on the grants and Chief Technology Officer of Diffinity, has appointments as Professor of Chemistry, Professor of Physics, Professor of Chemical Engineering, and Professor of Biophysics and Structural Biology at the University. “The NIH grants enable us to obtain the resources needed to accelerate the development of our unique technology into products for applications, such as gel extraction and enzyme removal, that our customers have been requesting from us”, said Dr. Rothberg. “We are focused on providing life science researchers and service providers with nucleic acid purification products that save them time and increases their productivity.”
About Diffinity Genomics, Inc. (www.diffinitygenomics.com) Safe Harbor Statement Contact: Robin Hodownes VP, Sales & Marketing Diffinity Genomics, Inc. 585-272-8141 rhodownes@diffinitygenomics.com ### |
